Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC Sales of Domestic Ethical Drugs Down 3.2% in April-September Period Due to Generic Competition
October 31, 2013
- DSP North America Sales Up 11.8% Due to Latuda, Japan Sales Down 4.2% in April-September Period
October 31, 2013
- Stock-Out of Mucosolate, Lemalc Due to Non-Conformance Results of Dissolution Testing, Stable Supply to Resume Next Spring: Teva Pharma Japan
October 31, 2013
- Teva Pharma Japan Notifies Customers of Stock-Out of Mucosolate L Cap.45, Lemalc Tab. 100 Due to Manufacturing Troubles
October 30, 2013
- Taiwan Approval Sought for DSP’s Antipsychotic Lurasidone
October 30, 2013
- Eli Lilly Italy Pres. Jönsson to Take Reins of Japan Operations
October 29, 2013
- Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
- Tamiflu Supply Plan for This Season Down by 3 Million Treatment Courses against Last Season: Chugai
October 25, 2013
- Race for Top Brands for BPH Tightens as Generics Make Inroads; OAB Market Grows as Disease Entity Becomes Better Defined
October 25, 2013
- Ono Licenses Pheochromocytoma Treatment Metyrosine from Valeant
October 24, 2013
- Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
- Shionogi, Nipro to Copromote Anti-Influenza Treatment Rapiacta
October 23, 2013
- Roche Still Tops in Patent Asset Ranking in Japan, Shionogi, MTPC Jumps to Second, Third Place
October 22, 2013
- Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey
October 22, 2013
- BMKK, Pfizer to Change Distribution Channel to Wholesalers for Eliquis, Remain as Copromoters
October 21, 2013
- CMIC Holdings Joins Hands with UK Firm Aesica in Contract Manufacturing Biz
October 21, 2013
- Santen Opens Office in Ho Chi Minh City
October 21, 2013
- Kissei, Kyorin Initiate PI Study of Overactive Bladder Treatment KEA-0447/KRP-EPA605
October 21, 2013
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…